Aspirin vs Anticoagulation in Carotid Artery Dissection: A Study of 298 Patients
Neurol 72:1810-1815,1800, Georgiadis,D.,et al, 2009
Statin Therapy After First Stroke Reduces 10-Year Stroke Recurrence and Improves Survival
Neurol 72:1816-1822, Milionis,H.J.,et al, 2009
Intravenous Thrombolysis in Stroke Attributable to Cervical Artery Dissection
Stroke 40:37772-3776, Engelter,S.,et al, 2009
Evaluation and Treatment of Inflammatory Myopathies
JNNP 80:1060-1068, Amato,A. &Barohn,R.J., 2009
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
Treatment of Neuromyelitis Optica with Mycophenolate Mofetil
Arch Neurol 66:1128-1133, Jacob,A.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
NEJM 361:1067-1074, Chen,Y.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Brainstem Lesions in Diffusion Sequences of MRI Can be Reversible After Arterial Recanalization
Neurol 73:813-815, Vilas,D., 2009
Combined Corticosteroid and Antiviral Treatment for Bell Palsy: A Systematic Review and Meta-analysis
JAMA 302:985-993, 1003, Almeida,J.,et al, 2009
Outcome of Symptomatic Intracranial Atherosclerotic Disease
Stroke 40:2983-2987, Samaniego,E.,et al, 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes
Stroke 40:3159-3160, 3163, Hackam,D., 2009
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009
Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Medial Medullary Infarction: Clinical, Imaging, and Outcome Study in 86 Consecutive Patients
Stroke 40:3221-3225, Kim,J. &Han,Y., 2009
Intraventricular Fibrinolysis and Lumbar Drainage for Ventricular Hemorrhage
Stroke 40:3275-3280, Staykov,D.,et al, 2009
Transcranial Ultrasound in Clinical Sonothrombolysis (TUCSON) Trial
Ann Neurol 66:28-38, Molina,C.A.,et al, 2009
Lamotrigine Kinetics Within the Menstrual Cycle, After Menopause, and with Oral Contraceptives
Neurol 73:1388-1393, Wegner,I.,et al, 2009
Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
Stroke 40:3526-3531,3413, Goldstein,L.,et al, 2009
Interventions in the Management of Serum Lipids for Preventing Stroke Recurrence
Stroke 40:e622-e623, Manktelow,B. &Potter,J., 2009
Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2
NEJM 361:358-367, Plotkin,S.R.,et al, 2009
Recurrent Cerebral Ischemia in Medically Treated Patent Foramen Ovale: A Meta-Analysis
Neurol 73:89-97,84, Almekhlafi,M.A.,et al, 2009
Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Arch Neurol 66:865-869, Orr,C.F. &Ahlskog,E., 2009
Intraarterial Thrombolysis Within the First Three Hours After Acute Ischemic Stroke in Selected Patients
Stroke 40:2611-2612,2615, Moonis,M., 2009
Is Intraarterial tPA Within 3 Hours the Treatment of Choice for Selected Stroke Patients? No
Stroke 40:2613-2614,2615, Lindley,R.I., 2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009
Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis
Stroke 40:2438-2441, Lansberg,M.G.,et al, 2009
Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Window Acute Stroke Therapy Trials
Stroke 40:2594-2600, Saver,J.L.,et al, 2009
A 70-Year-Old Woman with Shingles: Review of Herpes Zoster
JAMA 302:73-80,108, Whitley,R.J., 2009
Cyclophosphamide Therapy in Pediatric Multiple Sclerosis
Neurol 72:2076-2082,2064, Makhani,N.,et al, 2009
Use of Antithrombotic Drugs and the Presence of Cerebral Microbleeds: The Rotterdam Scan Study
Arch Neurol 66:714-720,691, Vernooij,M.W.,et al, 2009
Primary Angiitis of the Central Nervous System
Arch Neurol 66:704-709, Birnbaum,J. &Hellmann,D.B., 2009
Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation: A Randomised Non-Inferiority Trial
Lancet 374:534-542,504, Holmes,D.R.,et al, 2009
Antithrombotic Management of Patients with Prosthetic Heart Valves: Current Evidence and Future Trends
Lancet 374:565-576, Sun,J.C.J.,et al, 2009
Who Is Ineligible for Warfarin in Atrial Fibrillation?
Lancet 374:510-511, Verheugt,F.W.A., 2009
Isolated Lateral Sinus Thrombosis: A Series of 62 Patients
Stroke 40:476-481, Damak,M.,et al, 2009
Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Assessment of Potential Drug Interactions in Patients with Epilepsy: Impact of Age and Sex
Neurol 72:419-425, Gidal,B.E.,et al, 2009
Hemorrhage in Posterior Reversible Encephalopathy Syndrome: Imaging and Clinical Features
AJNR 30:1371-1379, Hefzy,H.M.,et al, 2009
Parkinsonism in HIV-Infected Patients on Highly Active Antiretroviral Therapy
Neurol 73:401-403, Tisch,S. &Brew,B., 2009
Toxic and Drug-Induced Myopathies
JNNP 80:832-838, Dalakas,M.C., 2009
Expansion of the Time Window for Treatment of Acute Ischemic Stroke with Intravenous Tissue Plasminogen Activator: A Science Advisory from the American Heart Association/American Stroke Association
Stroke 40:2945-2948, del Zoppo,G.J.,et al, 2009
MR Mismatch Is Useful for Patient Selection for Thrombolysis: Yes
Stroke 40:2906-2907,2910, Fiebach,J.B. &Schellinger,P.D., 2009
4.5 Hours: The New Time Window for Tissue Plasminogen Activator in Stroke
Stroke 40:2266-2267, Davis,S.M. &Donnan,G.A., 2009
Cerebral Microbleeds Are a Risk Factor for Warfarin-Related Intracerebral Hemorrhage
Neurol 72:171-176, Lee,S.-H.,et al, 2009